Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, ...

Europe, Ukraine hope for chilly Putin summit ▪ The Hill interview: Newsom defends redistricting fight ▪ Progressives take center stage in mayoral contests ▪ Israel steps up ...